Company intelligence / Profile preview
Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
Zhejiang Sheng, Chinabioworld.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Currently conducting Phase 1/2 clinical trials for TFX06 tablet in ER Positive, HER2 Negative Advanced Breast Cancer. Their PARP-1 inhibitors have shown significant antiproliferative activity against BRCA1 and BRCA2 mutated human breast MDA-MB-436 and colorectal DLD-1 cancer cells.
- Therapeutic areas
- OncologyCardiovascularNeurology
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Shenzhen Yangli Pharmaceutical Technology Co. Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Yangli Pharmaceutical Technology Co. Ltd..